Kornitzer Capital Management Inc. KS reduced its stake in shares of Omnicell, Inc. (NASDAQ:OMCL) by 1.9% during the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 152,520 shares of the company’s stock after selling 3,025 shares during the period. Kornitzer Capital Management Inc. KS owned approximately 0.39% of Omnicell worth $8,000,000 at the end of the most recent reporting period.
A number of other large investors have also recently added to or reduced their stakes in the business. BlackRock Inc. grew its holdings in Omnicell by 0.9% during the first quarter. BlackRock Inc. now owns 4,884,888 shares of the company’s stock worth $212,004,000 after acquiring an additional 45,697 shares during the period. Conestoga Capital Advisors LLC boosted its position in shares of Omnicell by 5.7% in the 2nd quarter. Conestoga Capital Advisors LLC now owns 1,833,223 shares of the company’s stock valued at $96,153,000 after purchasing an additional 98,515 shares during the period. Dimensional Fund Advisors LP boosted its position in shares of Omnicell by 1.4% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,538,878 shares of the company’s stock valued at $66,787,000 after purchasing an additional 20,902 shares during the period. Champlain Investment Partners LLC boosted its position in Omnicell by 3.2% during the 1st quarter. Champlain Investment Partners LLC now owns 1,505,445 shares of the company’s stock worth $65,336,000 after acquiring an additional 46,390 shares during the period. Finally, Westwood Holdings Group Inc. boosted its position in Omnicell by 23.0% during the 1st quarter. Westwood Holdings Group Inc. now owns 650,078 shares of the company’s stock worth $28,213,000 after acquiring an additional 121,460 shares during the period. Institutional investors own 98.80% of the company’s stock.
Omnicell stock traded up $0.75 on Friday, reaching $68.75. The company’s stock had a trading volume of 240,700 shares, compared to its average volume of 310,446. The firm has a market cap of $2.62 billion, a P/E ratio of 381.94, a P/E/G ratio of 3.30 and a beta of 0.91. Omnicell, Inc. has a twelve month low of $39.75 and a twelve month high of $69.40. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.27 and a current ratio of 1.78.
A number of equities research analysts have commented on the company. BidaskClub upgraded Omnicell from a “sell” rating to a “hold” rating in a research report on Saturday, May 5th. Zacks Investment Research raised Omnicell from a “sell” rating to a “hold” rating in a research note on Monday, August 13th. TheStreet raised Omnicell from a “c+” rating to a “b” rating in a research note on Friday, July 27th. Craig Hallum raised Omnicell from a “hold” rating to a “buy” rating and set a $33.00 price target on the stock in a research report on Friday, July 27th. Finally, ValuEngine raised Omnicell from a “hold” rating to a “buy” rating in a report on Wednesday, June 20th. Two investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. Omnicell has a consensus rating of “Buy” and an average target price of $53.80.
In other Omnicell news, EVP Nhat H. Ngo sold 20,436 shares of the stock in a transaction dated Thursday, July 5th. The stock was sold at an average price of $55.00, for a total value of $1,123,980.00. Following the completion of the sale, the executive vice president now directly owns 57,750 shares in the company, valued at $3,176,250. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Jorge R. Taborga sold 17,644 shares of the stock in a transaction dated Wednesday, August 1st. The stock was sold at an average price of $58.77, for a total value of $1,036,937.88. Following the completion of the sale, the executive vice president now owns 44,973 shares of the company’s stock, valued at $2,643,063.21. The disclosure for this sale can be found here. Insiders sold 86,845 shares of company stock valued at $4,660,212 in the last quarter. 3.71% of the stock is currently owned by corporate insiders.
Omnicell, Inc provides automation and business analytics software solutions for medication and supply management in healthcare worldwide. The company operates through two segments, Automation and Analytics, and Medication Adherence. It offers Omnicell Automated Dispensing Cabinets, a dispensing system, which automates the management and dispensing of medications; SinglePointe, a software product that controls medications; AnywhereRN, a software which remotely queue medications from automated dispensing cabinets; Omnicell Analytics and Pandora Analytics reporting and data analytics tools; and Anesthesia Workstation that manages anesthesia supplies and medications.
Read More: How Do I Invest in Dividend Stocks
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.